# US 12,178,840 B2 · Method and compositions comprising a CT20 peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,840 B2
- Document ID: US12178840B2
- Status: Granted
- Kind: B2
- Application number: 17/486,432
- Filed: 2021-09-27
- Published: 2022-03-31
- Granted: 2024-12-31
- Earliest claimed: 2014-07-18
- Assignees: University of Central Florida Research Foundation, Inc.
- Applicants: University of Central Florida Research Foundation, Inc.
- Inventors: Annette Khaled; Jesus Manuel Perez; Rania Bassiouni
- Web page: https://patentgrep.com/patent/US12178840B2

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- C12Q 1/025: {for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18)}
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are compositions comprising a CT20 peptide and methods of using the disclosed compositions to treat cancers expressing chaperonin containing TCP (CCT).

## Claims

### Claim 1

A method of treating a subject having lung cancer, the method comprising:
obtaining a lung tumor tissue sample from the subject;
measuring the amount of chaperonin containing TCP (CCTβ) in the lung tumor tissue sample using immunohistochemical staining;
assigning a score to the lung tumor tissue sample based on immunohistochemical staining intensity, wherein a score of 0 indicates no immunohistochemical staining for CCTβ, a score of 1 indicates faint, focal cytoplasmic immunohistochemical staining for CCTβ, a score of 2 indicates weak cytoplasmic immunohistochemical staining for CCTβ throughout the lung tumor tissue sample, a score of 3 indicates intense immunohistochemical staining for CCTβ that does not obscure cell nuclei, and a score of 4 indicates intense immunohistochemical staining for CCTβ that obscures cell nuclei; and
initiating a therapeutic regimen if the score of the lung tumor tissue sample is 1 or greater, wherein the therapeutic regimen comprises administering to the subject an effective amount of a composition comprising a CT20 peptide, and wherein the CT20 peptide comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the therapeutic regimen further comprises administration of an anti-cancer agent, an anti-neoplastic agent, a radiosensitizer, or a chemotherapeutic agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the CT20 peptide is delivered via nanoparticles.

### Claim 4 (depends on 3)

The method of claim 3, wherein the nanoparticles comprise at least one type of targeting moiety.

### Claim 5 (depends on 4)

The method of claim 4, wherein the targeting moiety comprises a ligand for a receptor expressed by lung cancer cells.

### Claim 6 (depends on 5)

The method of claim 5, wherein the receptor expressed by lung cancer cells is an EGF, HER2, or folate receptor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CT20 peptide further comprises an internalization domain.

### Claim 8 (depends on 1)

The method of claim 1, wherein the CT20 peptide further comprises a biotin label.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample comprises a tissue biopsy.

### Claim 10 (depends on 1)

The method of claim 1, wherein measuring the amount of CCTβ in the sample comprises quantifying the amount of CCT protein in the sample.

### Claim 11 (depends on 1)

The method of claim 1, wherein measuring the amount of CCTβ in the sample comprises quantifying the amount of CCTβ mRNA in the samples.

### Claim 12 (depends on 1)

The method of claim 1, further comprising administering to the subject an immunotherapy regimen.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immunotherapy regimen includes administration of an immune checkpoint inhibitor.